Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Corbeil Essonnes – page 220

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Corbeil Essonnes at a glance
3 332
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Cutaneous T-cell lymphoma+3

Not recruiting

Study of Mogamulizumab and Total Skin Electron Beam Therapy for Patients with Stage IB-IIB Cutaneous T-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mogamulizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Cutaneous T-cell lymphoma+1

Not recruiting

Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lacutamab
  • Sponsor:Innate Pharma

Metastatic malignant melanoma

Not recruiting

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Io Biotech ApS

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study on the Safety and Effectiveness of MK-1200 for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Soft tissue sarcoma

Not recruiting

Study on L19TNF and Doxorubicin for Patients with Advanced or Metastatic Soft Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Adenocarcinoma gastric+1

Not recruiting

Study of Zolbetuximab Alone and with Drug Combination for Patients with Advanced Stomach or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Astellas Pharma Global Development Inc.

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Perampanel for Children with Epilepsy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Perampanel
  • Sponsor:Eisai Limited

B-cell lymphoma+1

Not recruiting

Study of Axi-Cel, Fludarabine Phosphate, and Cyclophosphamide for Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Takeda Development Center Americas Inc.

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

  • Glycemic Control Studies
  • Cardiovascular Risk Management
  • Weight Management Therapies
02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

  • Novel Drug Combinations
  • Maintenance Therapy Optimization
  • Minimal Residual Disease Studies
03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

  • Immunotherapy Development
  • Alternative Treatment Strategies
  • Disease Management Protocols
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.